Treatment of severe atopic dermatitis with Tralokinumab in real clinical practice. Short-term effectiveness and safety results.

Abstract

Tralokinumab was recently approved for the treatment of moderate to severe AD and is the first selective IL-13 inhibitor that specifically neutralizes IL-13 with high affinity. To determine the real-life short-term effectiveness and safety of Tralokinumab treatment in AD patients with moderate to severe AD. A multicentre retrospective study was conducted including adult patients with moderate to severe AD who initiated Tralokinumab treatment from 1 April to 30 June 2022 in 16 spanish hospitals. Demographic and disease characteristics, severity and quality of life scales were collected at the baseline visit and at weeks 4 and 16. Eighty-five patients were included. Twenty-seven patients (31.8%) were non-naïve to advanced therapy (biological or JAK inhibitors). All included patients had severe disease with baseline EASI scores of 25.4 ± 8.1, DLQI 15.8 ± 5.4 and PP-NRS 8.1 ± 1.8. Sixty-five percent of the patients had an IGA of 4. At week 16, all scales improved significantly. The mean EASI decreased to 7.5 ± 6.9 (70.4% improvement), SCORAD improved 64.1% and PP-NRS, 57.1%. Also, 82.4%, 57.6% and 21.2% of the patients achieved EASI 50, 75 and 90, respectively. The percentage of EASI75 responders was significantly higher among naïve versus non-naïve patients (67.2% vs 40.7%). The safety profile was quite acceptable. Patients, with a long history of disease and prior multidrug failure, showed a good response to Tralokinumab, confirming clinical trial results.